Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
21. |
ECCT/23/05/01 | A5356 A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH CENTRE |
06-03-2024 |
View |
22. |
ECCT/23/11/01 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. AHERO CLINICAL TRIALS UNIT (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
20-02-2024 |
View |
23. |
ECCT/23/10/05 | CAPTURE-2 Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents with Plasmodium falciparum Malaria Infection. |
Principal Investigator(s) 1. Dr Lucas Otieno Tina Otieno Tina Site(s) in Kenya Victoria Biomedical Research Institute |
16-02-2024 |
View |
24. |
ECCT/22/10/03 | ISSC A randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics, and efficacy of escalating doses of oral ivermectin in scabies infected children weighing 5 to less than 15 kilograms in Kenya |
Principal Investigator(s) 1. Eunice Akinyi Ouma Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital |
14-02-2024 |
View |
25. |
ECCT/23/11/06 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. AHERO CLINICAL TRIALS UNIT (Kisumu county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
05-02-2024 |
View |
26. |
ECCT/23/10/07 | Fermented Food and Prediabetes A Study of the Hypoglycemic Effect of African Traditonal Fermented Foods amongst Prediabetic Adults. |
Principal Investigator(s) 1. Rosebella Iseme - Ondiek Site(s) in Kenya 1. Aga Khan Outreach Centre Nairobi CBD/Town (Nairobi City county) 2. Aga Khan Outreach Centre Valley Arcade (Nairobi City county) 3. Aga Khan Outreach Centre Capital Centre (Nairobi City county) 4. Aga Khan Outreach Centre Kiambu Town (Kiambu county) 5. Aga Khan Outreach Centre Juja (Kiambu county) 6. Aga Khan Outreach Centre Ruiru (Kiambu county) 7. Aga Khan Outreach Centre Ongata Rongai (Kajiado county) 8. Aga Khan Outreach Centre Ngong (Kajiado county) 9. Aga Khan Outreach Centre Kitengela (Kajiado county) |
17-01-2024 |
View |
27. |
ECCT/23/10/01 | CROSSWALK Chronic (C) A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c) |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Doreen Terry Karimi Site(s) in Kenya 1. Gertrudes Childrens Hospital (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
10-01-2024 |
View |
28. |
ECCT/23/07/01 | POWWeR Health Study Single arm trial of menstrual cups among economically vulnerable women to reduce Bacterial vaginosis and STIs through reduced harmful sexual and menstrual practices (POWWeR Health Study): A Phase 2 Trial |
Principal Investigator(s) 1. Fredrick Otieno 2. Supriya Dinesh Mehta Site(s) in Kenya Nyanza Reproductive Health Society |
20-12-2023 |
View |
29. |
ECCT/23/06/02 | IMAGINE-TBM A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM). |
Principal Investigator(s) 1. Deborah Chepng\'eno Langat Site(s) in Kenya KEMRI/WRP CRC |
24-10-2023 |
View |
30. |
ECCT/23/08/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Nduba Videlis Site(s) in Kenya 1. Getrudes Children Hospital (Nairobi City county) 2. KEMRI/CRDR (Siaya county) 3. Kombewa CRC (Kisumu county) 4. Kondele Childrens Hospital (Kisumu county) |
18-10-2023 |
View |